Remove Allergies Remove Antibody Remove Medicine Remove Vaccine
article thumbnail

HIV vaccines suffer setbacks but new approaches could turn the tide

Pharmaceutical Technology

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

article thumbnail

Monoclonal antibody could transform malaria prevention

Drug Discovery World

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa. . The antibody was up to 88.2% The Phase II NIAID-USTTB trial evaluated a one-time, intravenous infusion of a monoclonal antibody called CIS43LS. .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 Adapted Bivalent Vaccine Candidate

Pfizer

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 1 Adapted Bivalent Vaccine Candidate. Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 1 Adapted Bivalent Vaccine Candidate. 1 as compared to the companies’ current COVID-19 vaccine.

article thumbnail

More malaria hope as antibody protects against infection

pharmaphorum

A single dose of a monoclonal antibody developed by scientists at the US National Institutes of Health (NIH) has provided protection for people exposed to malaria parasites for up to nine months. The post More malaria hope as antibody protects against infection appeared first on.

article thumbnail

Antibody responses in COVID-19 patients could guide vaccine design

Scienmag

Credit: NIAID, 2020 A comprehensive analysis of antibody responses in coronavirus disease 2019 (COVID-19) patients could inform the development of an effective vaccine, according to a study published September 10 in the open-access journal PLOS Pathogens by Chao Wu and Rui Huang of Nanjing University Medical School, and colleagues.

article thumbnail

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

Pfizer

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted 5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age. Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted 5-adapted bivalent vaccine. 5) AUTHORIZED USES .

article thumbnail

UAB researcher develops technology to aid COVID-19 vaccine immunity monitoring

Scienmag

In advance of public vaccination, a quick and accurate COVID-19 antibody test will help determine the presence of neutralizing antibodies, the molecules that aid in protection against the virus. Credit: UAB BIRMINGHAM, Ala.